ASCENIV™ is the only IGIV
product available that is manufactured
using patented methodologies
for donor screening and plasma pooling*

About ASCENIV™ production:

ASCENIV™ is manufactured through a patented process using source plasma, which is acquired from donors screened using a microneutralization assay to detect and identify which donors possess naturally occurring neutralizing antibody titers to respiratory syncytial virus (RSV)1
  • Plasma pool is derived from a minimum of 1000 unique donors and blends normal source plasma with RSV plasma
  • Plasma collected from US FDA-licensed plasma collection centers
  • Meets potency requirements for 21CFR6401

*ADMA BIOLOGICS PATENTS ISSUED 9,107,906 - 9,714,283 - 9,815,886.